Prolia enters range of health insurance benefits based on excellent bone density improvement

‘Prolia(generic name: denosumab),’ an Amgen Korea’s first biological osteoporosis treatment, has been registered in the health insurance benefit list since the 1^st of October.

Prolia, the first and only osteoporosis treatment targeting RANKL, is a once-6-month hypodermic injection. After launched with no health insurance benefit in Korea on November 2016, the product successfully entered in th...